vatalanib has been researched along with triazoles in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (triazoles) | Trials (triazoles) | Recent Studies (post-2010) (triazoles) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 25,808 | 2,252 | 13,501 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| A'Hern, R; Banerjee, S; Detre, S; Dowsett, M; Evans, DB; Littlewood-Evans, AJ; Martin, LA | 1 |
1 other study(ies) available for vatalanib and triazoles
| Article | Year |
|---|---|
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Cell Proliferation; Female; Humans; Immunohistochemistry; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neovascularization, Pathologic; Nitriles; Phthalazines; Pyridines; Receptors, Estrogen; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2010 |